Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries. This is an ASCO Meeting Abstract from the 2025 ASCO ...

BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...

Predictions for identifying 1-year seizure recurrence performed significantly better in electroencephalography (EEG) without interictal epileptiform discharges. An automated processing algorithm ...